# Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct05093231/  
OnCo record `nct05093231` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab and olaparib in pancreatic cancer, run by Cambridge University Hospitals NHS Foundation Trust, now recruiting.

## Summary

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT05093231 by Cambridge University Hospitals NHS Foundation Trust, with a registry enrolment figure of 20 participants, started 2025-02-26 and due to reach its primary completion in 2027-07-31. Interventions recorded: Pembrolizumab; Olaparib. Conditions listed: Pancreatic Cancer. Primary outcome: Objective Response Rate (ORR). Sites: Australia, United Kingdom. United Kingdom sites listed: 15. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05093231
- Phase: 2
- Setting: A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With Mismatch Repair Deficiency or Tumour Mutation Burden > 4 Mutations/Mb
- Sponsor: Cambridge University Hospitals NHS Foundation Trust
- Enrolled: 20

## Notes

- UK sites (registry): Addenbrooke's Hospital (Cambridge); Glan Clwyd Hospital (Bodelwyddan); Velindre Cancer Centre (Cardiff); University Hospitals Coventry and Warwickshire (Coventry); Beatson West of Scotland Cancer Centre (Glasgow); St James' University Hospital (Leeds); Clatterbridge Cancer Centre (Liverpool); Guy's and St Thomas' NHS Foundation Trust (London); Royal Free Hospital (London); University College London Hospitals NHS Foundation Trust (London); The Christie (Manchester); Milton Keynes University Hospital (Milton Keynes) and 3 more.

## Sources

- ClinicalTrials.gov NCT05093231: https://clinicaltrials.gov/study/NCT05093231

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma](https://onco.cc/cancers/msi-high-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- trials: [POLO](https://onco.cc/trials/polo/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05093231.json